We compared the prevalence of serum hepatitis B virus (HBV) DNA in cancer patients who were immunocompromised with that in healthy subjects. Testing positive for serum HBV DNA were 27 of the 232 (11.6%) surface-antigen-negative cancer patients and 7 of the 382 (1.8%) surface-antigen-negative healthy subjects. These data suggest that the negative serology, at least in immunocompromised individuals, is probably not sufficient to exclude HBV infection.
Viral infections, including hepatitis B virus (HBV) infection, are common and well recognized in immunocompromised individuals, such as patients with leukemia or lymphoma, patients receiving chemotherapy for other malignant neoplasms (6) , and patients with end-stage renal failure on maintenance hemodialysis (5) . Serum HBV surface antigen (HBsAg) has been widely used as an early serological marker to identify HBV infection. DNA probes, which are designed for detecting specific nucleotide sequences, have been used more recently in the identification of an increasing number of bacterial and viral infections, including HBV infection (3) . It has been reported that the use of DNA probes of HBV is not only a sensitive method for detecting virus-associated HBV DNA sequences, but it is also specific and correlates with infectivity of serum as well as the physical parameters of the virus (1-3).
The purpose of this study was to investigate the prevalence of HBV infection based on the presence of serum HBV DNA in cancer patients who were immune deficient owing to leukemia or lymphoma or to chemotherapy. We further correlated the prevalence of HBV DNA with that of the serum HBsAg marker.
The subjects of this study were 322 patients with various types of malignant neoplasms ( DNA concentration of 10 pg or more per 0.1 ml of serum was interpreted as a positive result.
The cancer patients had a 28.0% HBsAg-positive rate, which was higher than the 21.4% HBsAg-positive rate of the healthy controls (P < 0.05; Table 2 ). HBV replication based on the presence of serum HBV DNA was found in 34.4 and 17.3% of the HBsAg-positive cancer patients and healthy control individuals, respectively (P < 0.01). More important, 11.6% of the HBsAg-negative cancer patients, who normally would have been considered not at risk for HBV infection, had HBV DNA in their sera. The type of neoplasm did not make a difference in which patients were HBV DNA positive or HBV DNA positive but HBsAg negative. The 11.6% rate was significantly higher than the 1.8% incidence observed in the healthy control group (P < 0.001). A total of 10 serum specimens from the 27 cancer patients who were HBsAg negative but HBV DNA positive were examined by electron microscopy, and typical 42-nm viral Dane particles were found in 8 specimens (Fig. 1) . All of the HBV DNA-positive but HBsAg-negative individuals in both groups were also negative for the HBV e antigen.
The higher than normal prevalence of HBV DNA in HBsAg-seronegative patients who were known to be immunosuppressed could be the result of one or a combination of the following possibilities. (i) The detection of HBV DNA by the DNA probe hybridization technique might be more sensitive than the determination of serum HBsAg marker by the radioimmunoassay method. (ii) Immunosuppression itself might lead to reactivation of latent HBV in these Rabbit anti-HBsAg antiserum (20 1.l) was allowed to react with 100 ,umol of patient serum overnight at room temperature. Goat antirabbit immunoglobulin G (20 il) coupled to colloid gold (average size of the gold particle, 10 nm) was then added to the reaction mixture. The reaction proceeded for another 4 h at room temperature. The pellets were then washed four times with 0.5 ml of phosphate-buffered saline. After the final wash, the pellet was suspended in 20 ptl of TEN (per liter, 50 mmol of Tris hydrochloride [pH 8.0], 1 mmol of EDTA, 150 mmol of NaCI). Aliquots (5 ,ul) were then negatively stained with uranyl acetate and examined by electron microscopy. Magnification, x 200,000.
patients. (iii) Intense chemotherapy might interfere with the release of viral antigen into serum (4) .
These data suggest that hepatitis infection and HBV replication may occur in immunosuppressed individuals while serological tests fail to detect the presence of virus and that negative serology, at least in this clinical setting, probably is not sufficient to exclude HBV infection, due to either primary infection or reactivation.
